Response to: Correspondence on ‘Beta-blockers are associated with better long-term survival in patients with Takotsubo syndrome’ by Chang et al

A. Silverio, M. Bellino, G. Galasso, E. Bossone, R. Citro
{"title":"Response to: Correspondence on ‘Beta-blockers are associated with better long-term survival in patients with Takotsubo syndrome’ by Chang et al","authors":"A. Silverio, M. Bellino, G. Galasso, E. Bossone, R. Citro","doi":"10.1136/heartjnl-2022-321263","DOIUrl":null,"url":null,"abstract":"The Authors’ reply We appreciate the interest of Dr Chang and Dr Liu in our study. Cardiogenic shock (CS) complicates the inhospital course of patients with takotsubo syndrome (TTS) in 6%–20% of cases and is the main cause of inhospital mortality. Treatment of CS in TTS is a clinical challenge and, due to the complexity of investigating this subject in dedicated randomised controlled trials, current evidence is limited to case reports or retrospective observational studies. The use of catecholamines in TTS complicated by CS is still debated since the administration of exogenous catecholamines might reexacerbate the acute phase and increase the risk of inhospital adverse events. In this scenario, previous case series have suggested the use of the Ca sensitiser levosimendan as a safe and feasible nonadrenergic alternative to common inotropic agents in TTS. Owing to the key role of catecholamine overstimulation in TTS pathophysiology, the use of betablockers has been proposed to mitigate the sympathetic drive and the effects of further catecholamine surges during the acute phase. In a monkey model of epinephrineinduced TTS, metoprolol improved left ventricular dysfunction, diminished the catecholamineinduced cardiomyocytolysis and modified the expression of heart failurerelated genes. However, in a recent propensity score matching analysis including 2110 Japanese patients with TTS, the early use of betablockers (started on hospitalisation day 1 or 2) did not influence patient 30day mortality. One interpretation of these conflicting results may be that the expected benefit of betablockers during the acute phase depends on the correct identification of the patient most likely to benefit. In TTS scenario, the early identification of patients at high risk of developing CS or with initial signs of haemodynamic instability constitutes the first step of an individualised patienttailored therapy. In a study from the INTERTAK Registry including 2078 patients with TTS, 198 (9.5%) developed CS. Some parameters easily detectable on admission including apical TTS, physical stress, lower left ventricular ejection fraction, diabetes mellitus and atrial fibrillation were associated with the risk of CS, hence emphasising their early detection for the identification of patients more prone to develop CS. We concur with Dr Chang and Dr Liu that betablockers should be considered in all patients after clinical stabilisation and before discharge, even in those who did not tolerate their early use. This certainly includes patients who developed CS during the acute phase, who have a significantly higher risk of developing adverse events compared with those without CS over the long term. 7 In our study, the prescription of betablockers at discharge was associated with a lower risk of mortality at longterm followup, particularly in patients with TTS who developed CS during the hospitalisation. This finding suggests that these patients may constitute a particular TTS phenotype characterised by higher sympathetic overdrive and greater susceptibility to catecholaminemediated myocardial damage. This result was also consistent with a previous study from RETAKO registry, which showed a significantly lower 1year mortality in patients who received betablockers compared with those who did not in the subset with CS during the hospitalisation. During the acute phase, the choice of the most appropriate treatment demands deep understanding of the multiple mechanisms potentially involved in haemodynamic instability. Although CS in TTS is generally attributable to acute pump failure, the haemodynamic deterioration can be determined by mechanical complication including dynamic left ventricular outflow tract obstruction (LVOTO) and functional transient mitral regurgitation. LVOTO is generally considered haemodynamically relevant if the gradient exceeds 50 mm Hg and represents a dynamic phenomenon closely related to the interactions between loading conditions and myocardial contractility. Rule out of LVOTO is usually achieved by transthoracic echocardiography. In patients undergoing coronary angiography and ventriculography, a slow pullback of pigtail catheter from left ventricle can exclude an intraventricular pressure gradient if TTS is suspected. While positive inotropes may be considered for the treatment of patients with primary pump failure, these agents should be possibly avoided in patients with TTS and LVOTO since they may increase basal myocardial contractility and worsen intraventricular gradient. In contrast to the therapy of acute heart failure with pulmonary oedema, diuretics are also not indicated in presence of LVOTO as they can further deteriorate intraventricular gradient through the preload reduction. In this setting, the use of shortacting betablockers such as esmolol or landiolol along with careful fluid administration have been proposed. In fact, these agents may reduce the hypercontractility of the basal segments and increase the ventricular preload with improvement of intraventricular gradient and of the haemodynamic status. In patients with refractory CS, shortterm mechanical circulatory support may also be considered as bridge to recovery, particularly in the presence of LVOTO. The use of Impella left ventricular assist device might restore haemodynamics by expelling aspirated blood from the left ventricle into the ascending aorta and skipping the left ventricular outflow tract. Conversely, intraaortic balloon pump is contraindicated since it leads to afterload decrease and to a worsening of intraventricular gradient. In case of refractory CS with multiple organ failure, the use of venoarterial extracorporeal membrane oxygenation may be considered depending on centre expertise and availability. Pending the definition of the best treatment for CS in TTS, based inevitably on the pathophysiological mechanism involved, our study suggests that betablockers should be started once adequate haemodynamic conditions have been restored, and maintained over time.","PeriodicalId":9311,"journal":{"name":"British Heart Journal","volume":"108 1","pages":"1244 - 1245"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Heart Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/heartjnl-2022-321263","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The Authors’ reply We appreciate the interest of Dr Chang and Dr Liu in our study. Cardiogenic shock (CS) complicates the inhospital course of patients with takotsubo syndrome (TTS) in 6%–20% of cases and is the main cause of inhospital mortality. Treatment of CS in TTS is a clinical challenge and, due to the complexity of investigating this subject in dedicated randomised controlled trials, current evidence is limited to case reports or retrospective observational studies. The use of catecholamines in TTS complicated by CS is still debated since the administration of exogenous catecholamines might reexacerbate the acute phase and increase the risk of inhospital adverse events. In this scenario, previous case series have suggested the use of the Ca sensitiser levosimendan as a safe and feasible nonadrenergic alternative to common inotropic agents in TTS. Owing to the key role of catecholamine overstimulation in TTS pathophysiology, the use of betablockers has been proposed to mitigate the sympathetic drive and the effects of further catecholamine surges during the acute phase. In a monkey model of epinephrineinduced TTS, metoprolol improved left ventricular dysfunction, diminished the catecholamineinduced cardiomyocytolysis and modified the expression of heart failurerelated genes. However, in a recent propensity score matching analysis including 2110 Japanese patients with TTS, the early use of betablockers (started on hospitalisation day 1 or 2) did not influence patient 30day mortality. One interpretation of these conflicting results may be that the expected benefit of betablockers during the acute phase depends on the correct identification of the patient most likely to benefit. In TTS scenario, the early identification of patients at high risk of developing CS or with initial signs of haemodynamic instability constitutes the first step of an individualised patienttailored therapy. In a study from the INTERTAK Registry including 2078 patients with TTS, 198 (9.5%) developed CS. Some parameters easily detectable on admission including apical TTS, physical stress, lower left ventricular ejection fraction, diabetes mellitus and atrial fibrillation were associated with the risk of CS, hence emphasising their early detection for the identification of patients more prone to develop CS. We concur with Dr Chang and Dr Liu that betablockers should be considered in all patients after clinical stabilisation and before discharge, even in those who did not tolerate their early use. This certainly includes patients who developed CS during the acute phase, who have a significantly higher risk of developing adverse events compared with those without CS over the long term. 7 In our study, the prescription of betablockers at discharge was associated with a lower risk of mortality at longterm followup, particularly in patients with TTS who developed CS during the hospitalisation. This finding suggests that these patients may constitute a particular TTS phenotype characterised by higher sympathetic overdrive and greater susceptibility to catecholaminemediated myocardial damage. This result was also consistent with a previous study from RETAKO registry, which showed a significantly lower 1year mortality in patients who received betablockers compared with those who did not in the subset with CS during the hospitalisation. During the acute phase, the choice of the most appropriate treatment demands deep understanding of the multiple mechanisms potentially involved in haemodynamic instability. Although CS in TTS is generally attributable to acute pump failure, the haemodynamic deterioration can be determined by mechanical complication including dynamic left ventricular outflow tract obstruction (LVOTO) and functional transient mitral regurgitation. LVOTO is generally considered haemodynamically relevant if the gradient exceeds 50 mm Hg and represents a dynamic phenomenon closely related to the interactions between loading conditions and myocardial contractility. Rule out of LVOTO is usually achieved by transthoracic echocardiography. In patients undergoing coronary angiography and ventriculography, a slow pullback of pigtail catheter from left ventricle can exclude an intraventricular pressure gradient if TTS is suspected. While positive inotropes may be considered for the treatment of patients with primary pump failure, these agents should be possibly avoided in patients with TTS and LVOTO since they may increase basal myocardial contractility and worsen intraventricular gradient. In contrast to the therapy of acute heart failure with pulmonary oedema, diuretics are also not indicated in presence of LVOTO as they can further deteriorate intraventricular gradient through the preload reduction. In this setting, the use of shortacting betablockers such as esmolol or landiolol along with careful fluid administration have been proposed. In fact, these agents may reduce the hypercontractility of the basal segments and increase the ventricular preload with improvement of intraventricular gradient and of the haemodynamic status. In patients with refractory CS, shortterm mechanical circulatory support may also be considered as bridge to recovery, particularly in the presence of LVOTO. The use of Impella left ventricular assist device might restore haemodynamics by expelling aspirated blood from the left ventricle into the ascending aorta and skipping the left ventricular outflow tract. Conversely, intraaortic balloon pump is contraindicated since it leads to afterload decrease and to a worsening of intraventricular gradient. In case of refractory CS with multiple organ failure, the use of venoarterial extracorporeal membrane oxygenation may be considered depending on centre expertise and availability. Pending the definition of the best treatment for CS in TTS, based inevitably on the pathophysiological mechanism involved, our study suggests that betablockers should be started once adequate haemodynamic conditions have been restored, and maintained over time.
对Chang等人关于“β受体阻滞剂与Takotsubo综合征患者更好的长期生存相关”的回应
我们感谢张博士和刘博士对我们研究的兴趣。在6%-20%的病例中,心源性休克(CS)使takotsubo综合征(TTS)患者的住院过程复杂化,是导致住院死亡的主要原因。TTS中CS的治疗是一项临床挑战,由于在专门的随机对照试验中研究该受试者的复杂性,目前的证据仅限于病例报告或回顾性观察性研究。儿茶酚胺在合并CS的TTS中的使用仍存在争议,因为外源性儿茶酚胺的给药可能会使急性期复发并增加住院不良事件的风险。在这种情况下,先前的病例系列建议使用钙增敏剂左西孟丹作为TTS中常见致力剂的安全可行的非肾上腺素替代品。由于儿茶酚胺过度刺激在TTS病理生理学中的关键作用,已经提出使用β受体阻滞剂来减轻急性期交感神经驱动和儿茶酚胺进一步激增的影响。在肾上腺素诱导的TTS猴子模型中,美托洛尔改善了左心室功能障碍,减少了儿茶酚胺诱导的心肌细胞溶解,并改变了心力衰竭相关基因的表达。然而,在最近一项包括2110名日本TTS患者的倾向评分匹配分析中,早期使用β受体阻滞剂(从住院第1或第2天开始)不会影响患者30天的死亡率。对这些相互矛盾的结果的一种解释可能是,β受体阻滞剂在急性期的预期益处取决于最有可能受益的患者的正确识别。在TTS的情况下,早期识别患有CS的高风险患者或具有血液动力学不稳定初始迹象的患者是个性化患者定制治疗的第一步。INTERTAK注册中心的一项研究包括2078名TTS患者,其中198人(9.5%)出现CS。入院时容易检测到的一些参数,包括心尖TTS、身体压力、左心室射血分数较低、糖尿病和心房颤动,与CS的风险相关,因此强调其早期检测,以识别更容易发展为CS的患者。我们同意张博士和刘博士的观点,即在临床稳定后和出院前,所有患者都应考虑使用β受体阻滞剂,即使是那些不耐受早期使用的患者。这当然包括在急性期发生CS的患者,与长期没有CS的患者相比,他们发生不良事件的风险明显更高。7在我们的研究中,出院时开具β受体阻滞剂与长期随访中较低的死亡率相关,尤其是在住院期间出现CS的TTS患者中。这一发现表明,这些患者可能构成一种特殊的TTS表型,其特征是交感神经过度兴奋和对儿茶酚胺介导的心肌损伤的易感性更高。这一结果也与RETAKO注册中心先前的一项研究一致,该研究显示,在住院期间,接受β受体阻滞剂治疗的患者的1年死亡率明显低于未接受CS治疗的患者。在急性期,选择最合适的治疗方法需要深入了解血液动力学不稳定可能涉及的多种机制。尽管TTS中的CS通常可归因于急性泵衰竭,但血液动力学恶化可由机械并发症决定,包括动态左心室流出道梗阻(LVOTO)和功能性短暂性二尖瓣反流。如果梯度超过50毫米汞柱,LVOTO通常被认为与血液动力学相关,并且代表了与负荷条件和心肌收缩性之间的相互作用密切相关的动态现象。LVOTO的排除通常通过经胸超声心动图来实现。在接受冠状动脉造影和心室造影的患者中,如果怀疑TTS,从左心室缓慢回撤猪尾导管可以排除心室内压力梯度。虽然原发性泵衰竭患者的治疗可以考虑使用阳性的促收缩剂,但TTS和LVOTO患者应尽量避免使用这些药物,因为它们可能会增加基础心肌收缩力并恶化心室内梯度。与治疗肺水肿的急性心力衰竭相比,利尿剂在LVOTO存在的情况下也不适用,因为它们可以通过预负荷减少进一步恶化心室内梯度。在这种情况下,有人建议使用短效β受体阻滞剂,如艾司洛尔或兰地洛尔,同时小心液体给药。 事实上,这些药物可以降低基底节段的高收缩性,并随着心室内梯度和血液动力学状态的改善而增加心室预负荷。对于难治性CS患者,短期机械循环支持也可被视为恢复的桥梁,特别是在存在LVOTO的情况下。Impella左心室辅助装置的使用可以通过将吸入的血液从左心室排出到升主动脉并跳过左心室流出道来恢复血流动力学。相反,主动脉内球囊泵是禁忌的,因为它会导致后负荷降低和心室内梯度恶化。在多器官衰竭的难治性CS的情况下,根据中心的专业知识和可用性,可以考虑使用静脉-动脉体外膜肺氧合。在确定TTS中CS的最佳治疗方法之前,不可避免地基于所涉及的病理生理机制,我们的研究表明,一旦恢复了足够的血液动力学条件,就应该开始使用β受体阻滞剂,并随着时间的推移而保持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信